Genzyme Corporation Receives European Approval For Synvisc(R) In Ankle And Shoulder Osteoarthritis Indications

CAMBRIDGE, Mass., Oct. 2 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has received European approval to expand the CE mark labeling for Synvisc(R) (hylan G-F 20) to include treatment of pain due to osteoarthritis (OA) of the ankle and shoulder. Approval of this new label will broaden the use of Synvisc beyond its established use in knee and hip OA patients. Synvisc has been shown in European clinical trials to provide up to twelve months of pain relief in knee OA.

"We are very pleased with this approval to expand the Synvisc label in Europe to now include the ankle and shoulder joints," stated Ann Merrifield, president of Genzyme Biosurgery, the business unit that manufactures and markets Synvisc. "We are eager to begin our marketing and sales effort and will continue to emphasize the strong clinical data that Synvisc has now generated in four major joints."

The approval of Synvisc in the ankle and shoulder follows clinical studies that were conducted in Europe in these two joints, and the filing of data from these trials. The studies were prospective, multi-center, open investigations that took place in several countries throughout Europe. Both studies found treatment with 1 or 2 injections of Synvisc to be well-tolerated, and data show that Synvisc significantly decreases pain due to OA in the ankle and shoulder.

Data from the ankle study have been accepted for presentation at the American College of Rheumatology (ACR) meeting this fall in Washington, D.C. and data from the shoulder study at the American Academy of Orthopaedic Surgeons (AAOS) meeting in San Diego, February 2007. Both abstracts also will be presented at the Osteoarthritis Research Society International (OARSI) congress in Prague in December. Genzyme expects to immediately begin marketing Synvisc in the European Union with its new label.

A Market Leader Powered by Clinical Benefit

These new data on ankle and shoulder add to the vast clinical evidence that further supports Synvisc's use in treating major joints affected by OA.

Recently announced data from an independent investigator's clinical study found Synvisc to be superior in magnitude and duration of pain relief, functional improvement and patient satisfaction to another viscosupplementation product in treating patients with OA of the knee. These independent data were presented last June at the European League Against Rheumatism (EULAR) meeting in Amsterdam, The Netherlands, and also at the British Orthopaedic Association congress held this month in Glasgow.

Genzyme is utilizing evidence-based medicine in broadening Synvisc label claims that further establish its efficacy and safety. In addition, two meta-analyses in 2004 and 2006 also affirmed the clinical benefit of Synvisc and its class of viscosupplements. These studies were conducted using research methodologies that provide physicians and payers with tools to evaluate new treatments using an evidence-based approach. In addition to its efficacy in relieving OA knee pain, Synvisc, as a non-systemic treatment, has the advantage of avoiding some of the side effects associated with some non-steroidal anti-inflammatory drugs including the COX-2 inhibitors.

Synvisc is marketed in more than 60 countries and has been used to treat more than 3 million people. Synvisc is currently approved in the United States for treatment of pain due to osteoarthritis of the knee. Genzyme is pursuing a label expansion in the U.S. that would include the hip indication.

About Synvisc

Synvisc is indicated for the treatment of pain due to osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, for example, acetaminophen. Synvisc is currently approved in Europe and Canada to treat pain due to osteroarthritis in both the knee and hip.

In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely. Synvisc is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Healthcare practitioners should exercise caution when using Synvisc in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of Synvisc in children and in pregnant or lactating women have not been established. It is unknown whether Synvisc is excreted in human milk.

About Genzyme Corporation

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme's founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

This press release contains forward-looking statements, including the statements regarding whether the expanded label indication for Synvisc will broaden its use beyond its established use in the knee and hip, whether we are ultimately able to obtain approval for the hip indication in the United States and the timing of commencement of our efforts to market the ankle and shoulder indications in Europe. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, our ability to effectively market the ankle and shoulder indications in Europe, the market's acceptance of the therapeutic benefits of Synvisc for the treatment of pain associated with osteoarthritis of the ankle and shoulder, our ability to launch a marketing campaign for the new shoulder and ankle indications while continuing to market Synvisc for the treatment of pain associated with osteoarthritis of the knee and hip, our ability to obtain marketing approval for the hip indication from the U.S. Food and Drug Administration, and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Please see the discussion under the heading "Factors Affecting Future Operating Results" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2006 for a more complete discussion of these and other risks. Genzyme cautions investors not to place substantial reliance on the forward- looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Synvisc(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.

Media Contact: Investor Contact: Dan Quinn Sally Curley 617-768-6849 617-768-6140

Genzyme Corporation

CONTACT: Dan Quinn, +1-617-768-6849, or Sally Curley, +1-617-768-6140,both of Genzyme

Back to news